With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of ...

GSK plc GSK announced that its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet the primary ...

Sanofi and development and manufacturing lead AstraZeneca continue to work together ... The company plans to be "more ...

GSK has shared positive headline results for its mRNA seasonal influenza vaccine and outlined that it will now progress the ...

GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement TÜBINGEN, Germany/BOSTON, USA – September 12, 2024 – CureVac N.V ...

LONDON, UK I 12, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal ...

"GSK continues to develop and optimise its mRNA capabilities through investments and partnerships, including in AI/ML-based sequence optimisation, nanoparticle design and manufacturing," it said ...

Fidson, which is listed in Lagos where its stock has shed 24.6 per cent this year, is valued at N30.3 billion.

GSK announced promising results from its phase two clinical trial for an mRNA-based seasonal flu vaccine on Thursday.

DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...